Objective: Chitosaneglycerol phosphate (chitosan-GP) is a unique polymer solution that is mixed with whole blood and solidified over microfractured or drilled articular cartilage defects in order to elicit a more hyaline repair cartilage. For clinical ease-of-use, a faster in situ solidification is preferred. Therefore, we investigated the mechanisms underlying chitosaneGP/blood implant solidification.
Introduction
A current aim and major challenge in orthopedic practice is to regenerate durable cartilage in focal articular lesions 1e3 . Cartilage is avascular and when damaged fails to bleed and therefore lacks an efficient wound repair response. To stimulate a natural wound response, surgeons have developed techniques like bone marrow stimulation involving drilling or microfracture in the base of the dé brided cartilage lesion to induce subchondral bleeding and generate conduits to permit bone marrow stem cell migration into the cartilage lesion 3e6 . However in skeletally mature human patients and animal models, these surgical techniques principally result in the formation of a repair tissue predominantly composed of fibrous tissue or fibrocartilage, tissue types with weak biomechanical properties compared to hyaline articular cartilage 2,5,7e13 . Treatments that improve the volume, integration, and hyaline quality of marrow-derived repair tissue are therefore the focus of intense research. Bleeding and the formation of a blood clot are initiating events of microfracture therapy 6 , however the clot is best retained in the bone defect and not on the cartilage surface 14e16 . To improve clot retention in the cartilage lesion following microfracture and drilling, we previously developed a scaffold-stabilized blood clot using chitosan, a cationic, adhesive and biocompatible polysaccharide. Homogenous mixtures of autologous whole blood and solutions of chitosaneglycerol phosphate (chitosaneGP) solidify to form a clot with morphologically normal erythrocytes and a structurally stable fibrous network with chitosan and fibrin fibers 17, 18 . Hybrid chitosan clots resist platelet-mediated clot retraction, and remain voluminous, firm and elastic 17 . The formation of a chitosaneGP/blood clot in marrow-stimulated cartilage defects in sheep and rabbit improved the quantity, hyaline quality and integration of repair cartilage with porous subchondral bone compared to repair tissue formed by microfracture or drilling alone 17, 19 . Hybrid clots were shown to promote hyaline repair by attracting neutrophils, marrow-derived repair cells, and by stimulating transient angiogenesis and bone remodeling 15 .
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Mixture of liquid chitosaneGP into whole blood generates a hybrid clot implant that forms within 10e15 min after depositing in large animal or patient microfracture defects 19, 20 . A more rapid implant solidification could facilitate treatment of larger defects with curved surfaces and unconfined borders, and also reduce the length of the cartilage repair procedure. Indeed, for clinician ease-of-use, a faster and controlled in situ solidification is preferred; however solidification mechanisms are incompletely understood. Many studies previously demonstrated that acidic chitosan solutions and solid chitosan particles are thrombogenic, through mechanisms involving red blood cell (RBC) agglutination, and platelet activation, without direct activation of the clotting cascade 17,21e23 . By comparison, little is understood concerning the hemostatic properties of isotonic and near-neutral pH chitosaneGP solutions.
The first aim of the current study was to elucidate solidification mechanisms of chitosaneGP/blood in vitro, using a Thromboelastograph Ò (TEG), an instrument that measures clotting time and clot tensile strength. We tested the hypothesis that chitosaneGP/blood solidification is thrombin-dependent, and furthermore implicates platelet and Factor XIII activation. The second aim of this study was to develop novel methods to accelerate in situ solidification in an in vivo animal cartilage repair model. We therefore tested the hypothesis that in vivo solidification of chitosaneGP/blood mixtures in microdrilled articular cartilage defects can be accelerated using clotting factors including thrombin (IIa), tissue factor (TF) and recombinant human factor VIIa (rhFVIIa). Tissue factor is a transmembrane receptor constitutively expressed in mainly extravascular tissues. TF binding with trace amounts of activated FVIIa that are present in plasma 24 triggers the extrinsic clotting cascade and thrombin generation. In our in vivo experiments, we used a recombinant TFephospholipid preparation at concentrations previously employed in clinical applications for maxillary bone grafts 25 , rhFVIIa at concentrations around threefold greater than the target plasma levels for clinical applications (w2 mg/mL) 26 , and thrombin concentrations within the low range used in standard fibrin glue 27 . Our choice of these particular factors was thus based on their known ability to promote repair processes, as well as their current use in other clinical contexts which could help translate their use in cartilage repair strategies involving polymereblood implants.
Materials and methods

MATERIALS
Medical-grade sterile solutions of chitosan (2.05% w/v, 80% degree of deacetylation, DDA, 1200-2000 mPa s., pH 5.6, <100 EU/mL endotoxins units and <5 ppm heavy metal content) and 500 mM disodium b-glycerol phosphate/50 mM HCl pH 7.1 (GP) were provided by Bio Syntech Inc (Laval, QC, Canada). ChitosaneGP solutions were formed aseptically by combining 1.2 mL chitosaneHCl with 0.3 mL GP. Rhodamine B-isothiocyanate (RITC)echitosan 0.5% mol/mol RITC/chitosan (80.5% DDA, M n 144 kDa, polydispersity (M w /M n ) 1.3) was prepared as 5 mg/mL filter-sterile solutions as previously described 28 . Calibrated viscosity standards (N62000, N1000, S60) were from Canon Instrument Company (State College, PA, USA) and silicon oil (pure silicone fluid) was from Clearco Products (Bensalem, PA, USA 30 . Venous peripheral whole blood was drawn from healthy non-fasting consented donors (three males and eight females, 29e47 years old, with one male and two females studied twice), according to institutional ethics approved protocols. A first blood draw was used to generate chitosaneGP/blood mixtures, and a second blood draw from the same donor was performed within 3 h to analyze unmodified whole blood. Blood was mixed with chitosaneGP at a 3:1 v/v ratio by vigorous shaking for 10 s in glass mixing vials containing six sterile surgical stainless steel mixing beads (0.39 g each, Salem Specialty Ball Co., Canton, CT) as described 17 . Unmodified whole blood was transferred to sterile borosilicate mixing vials to control for exposure to glass prior to transferring into TEG reaction cups. TEG plastic reaction cups (made of Cyrolite G20) were pre-loaded with 40 mL of either tPA (2 mg/mL in PBS with 4% w/v BSA), or clotting factor diluted in RLS to give the following target concentrations after adding 320 mL sample: 0.08e10 U/mL IIa; 5 mg/mL rhFVIIa; 0.7e278 pM TF; and rhFVIIa þ TF (5 mg/mL rhFVIIa þ 0.7 pM TF). Clot tensile strength was recorded manually as the amplitude (the distance in mm on the y-axis between the two traces). At set time intervals, the whole reaction cup was transferred to ice cold quench buffer (20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 150 mM NaCl, 50 mM ethylenediaminetetraacetic acid (EDTA), 10 mM benzamidine, 33 mM FPR-ck, pH 7.4) at a 1:9 ratio of blood:quench buffer, vortexed for 10 s, cleared by a double centrifugation (2500g, 15 min, 4 C) and kept as aliquots at À80 C until analyzed for thrombin generation by TAT ELISA 30 , or by Western blot for platelet activation by appearance of serum PF4 31 and for activation of FXIII as determined by cleavage of FXIII A subunit 32 . The equivalent of 4 mL serum, also adjusted for dilution of blood by chitosaneGP, was loaded into each well of a 17.5% acrylamide non-reducing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) for PF4 and 2 mL serum on a 10% acrylamide SDS-PAGE reducing gel for the A and B subunits of FXIII. Proteins were transferred to polyvinylidene fluoride (PVDF) membrane, blocked for 1 h with 5% non-fat milk powder in 50 mM Tris, 150 mM NaCl, 0.1% Tween-20 pH 7.4 (TBST) at 50 C, and probed with goat anti-PF4 (0.2 mg/mL) then 1:10,000 diluted affinity-purified donkey anti-goat-HRP (0.08 mg/mL) or Sheep anti-human A and B subunits of FXIII antibody (9.8 mg/mL) and donkey anti-sheep-HRP (0.08 mg/mL), followed by chemiluminescence (Lumi-Light). Purified proteins were used as positive controls for PF4 (20 ng/well) and FXIII (0.22 mg/well).
IN VIVO ARTICULAR CARTILAGE REPAIR MODEL
All animal experimentation was carried out with protocols approved by the University of Montreal Animal Division, using skeletally mature New Zealand White rabbits (N ¼ 33 rabbits, 16 males, 17 females, >8 months randomly assigned to different groups; 8 out of these 33 rabbits received bilateral knee implants for a total of N ¼ 41 unilateral or bilateral defects treated with implant, see Table I ). Rabbits were anesthetized with an intramuscular injection of ketamineexylazineebuprenorphine cocktail then placed under 3% isoflurane/8% oxygen gas anesthesia. They were subjected to small knee arthrotomies in order to create bilateral 3.5 Â 4 mm 954 C. Marchand et al.: ChitosaneGP/blood solidification mechanisms trochlear defects debrided into the calcified layer 17 . All defects were pierced with microdrill holes (either two distal 0.9 mm drill holes and six proximal 0.5 mm drill holes, or four 0.9 mm drill holes) with constant irrigation of cold sterile RLS buffer to keep cartilage humid as previously described 15, 17 . Fresh non-activated autologous rabbit blood was drawn from the central ear artery and mixed at a 3:1 v/v ratio with chitosaneGP. For some implants, 500 mL of chitosaneGP was further combined with 100 mL RITCechitosan prior to mixing with 1.5 mL blood (see Table I , treatment group 4). Control chitosaneGP/blood implants were delivered from a 1 cc syringe and 20 gauge needle as one hanging drop without clotting factor. In some defects, rhFVIIa was mixed into whole blood to obtain 10 mg/mL rhFVIIa (200 nM) prior to combining with chitosaneGP. In other defects, 3 mL of concentrated clotting factor was pipetted on the defect surface w60 s prior to liquid implant, either IIa (15 or 45 U/mL, for a target final concentration of 2 or 6 U/mL, respectively) or rhFVIIa þ TF [5 mg/mL rhFVIIa and 4.75 nM TF] (see Table I ). Finally, in four defects, thrombin (45 U/mL) was ''co-delivered'' by pipetting 3 mL of on the defect surface within 10 s of applying chitosaneGP/blood implant. In situ solidification time of the hybrid clot implants was noted for each implant according to the animal surgeon's observations. After re-positioning the patella, knees were closed in sutured layers.
STATISTICAL ANALYSIS
Statistica (version 6.1, StatSoft, Tulsa, OK, USA) software was used for multivariate correlation analysis to test TAT as a predictor of clot tensile strength, and the non-parametric KruskaleWallis test to evaluate the effect of clotting factor on in vivo implant solidification time. The Student t-test was used to determine the effect of chitosaneGP on maximum amplitude, of added clotting factors on clotting time and clot tensile strength at 5 and 15 min. P < 0.05 was considered to be significant.
Results
BIPHASIC SOLIDIFICATION OF CHITOSANeGP/BLOOD MIXTURES
Unmodified whole blood coagulated in the plastic TEG sample cup around 15 min after sample deposition [ Fig. 1(A) ]. By contrast, chitosaneGP/blood solidified in an atypical biphasic manner, with a rapid and stable increase in viscosity that at 5 min was significantly higher than whole blood [P < 0.001, 1.1 vs 0.2 mm, Fig. 1 (B) and (C)]. The polymereblood initial amplitude was also w3Â greater than that of the viscous chitosan solution prior to mixing with GP and blood, and 5Â greater than chitosaneGP mixed with water instead of blood (Table II) . These data demonstrated that the rapid thickening of chitosaneGP/blood mixtures was due to polymereblood interactions. ChitosaneGP/blood mixtures had an average clotting time of 21 min, and fully solidified over an average 66 min period, while unmodified whole blood took an average 43 min to reach peak clot strength [time to maximum amplitude, TMA, Fig. 1(C) ]. The peak clot tensile strength was similar for whole blood and chitosaneGP/blood [55.2 vs 51.8 mm, Fig. 1(C) ]. Addition of tPA at 10-fold higher concentration over normal plasma levels 33, 34 completely dissolved whole blood clots after 2 h [ Fig. 1(A) and (C)], while chitosaneGP/blood clots resisted complete lysis by tPA at the same concentration [P < 0.05, Fig. 1(B) ].
THROMBIN, PLATELETS AND FXIII ARE ACTIVATED DURING CHITOSANeGP/BLOOD SOLIDIFICATION Whole blood and chitosaneGP/blood solidification was paralleled by the same sequential order of clotting events, starting with thrombin generation at around 15 min followed by burst platelet activation (PF4) (Fig. 2) . Western blot analysis of FXIIIA and B subunits revealed a modest depletion of the A subunit relative to B, immediately prior to peak clot tensile strength, suggesting that proteolytic activation in the A subunit by thrombin had occurred [ Fig. 2(B) ]. ChitosaneGP/blood mixtures demonstrated a unique, minor platelet activation starting at 5 min, coinciding with the first phase of increased polymereblood viscosity [see PF4, Fig. 2(B) ]. Activation of platelets at these low levels was most probably not triggered by thrombin generation, since TAT was only detected after a 15 min delay in chitosaneblood mixtures. TAT and PF4 levels were sustained in chitosaneGP/blood mixtures up to 75 min [ Fig. 2(B) ], while both TAT and PF4 levels declined in parallel in whole blood clot serum after peak clot tensile strength was achieved [ Fig. 2(A) ]. By multivariate correlation analysis, thrombin generation was a highly significant predictor of clot tensile strength for whole blood [P < 0.00001, Fig. 2(C) ] and chitosaneGP/blood [P < 0.00001, Fig. 2(D) ]. These data demonstrated that chitosaneGP/blood mixtures, like whole blood, solidified through a thrombin-dependent mechanism.
CLOTTING FACTORS RAPIDLY INCREASE CHITOSANeGP/BLOOD CLOT TENSILE STRENGTH
Addition of a variety of clotting factors (thrombin, TF, rhFVIIa, or rhFVIIa þ TF) to the in vitro TEG sample cup prior to addition of whole unmodified blood and chitosane GP/blood resulted in a striking decrease in clotting time (P < 0.05, except for 0.08 U/mL IIa where P ¼ 0.3) . Tissue factor, with or without rhVIIa, induced the most rapid solidification of chitosaneGP/blood clots [ Fig. 3(F) ]. Altogether, these data showed that exposure of liquid chitosaneGP/blood mixtures to a small volume of concentrated clotting factor could accelerate solidification in vitro. When thrombin was homogeneously mixed into chitosaneGP prior to adding blood, however, the thrombine polymereblood mixture rapidly solidified in the mixing vial (unpublished observations). This indicated that clotting factor should be pre-applied or co-applied to cartilage defects to accelerate in vivo solidification.
CLOTTING FACTORS SHORTEN IN SITU CHITOSANeGP/BLOOD IMPLANT SOLIDIFICATION TIME
In microdrilled full-thickness cartilage defects in rabbit trochlea [ Fig. 4(A) ], chitosaneGP/blood mixtures solidified in situ with a delay of 5.0 min [ Fig. 4(C), condition 1] . The implant was confirmed as solidified when it no longer ran off the tilted defect or was no longer liquid when probed with a blunt instrument. The time lapse between defect creation and implant loading was between 5 and 10 min, which could theoretically lead to variability in microdrill hole hemostasis at the time of implant application. However no correlation was found between delay in application and in situ solidification time without added clotting factors (data not shown). This suggested that delayed in situ solidification was most probably due to a variable delay in clot activation in chitosaneGP/blood mixtures, and in some cases due to a low level of bleeding from subchondral bone. With the aim of improving the rate of in situ solidification, two methods were used to combine clotting factors with chitosaneGP/blood: (1) rhVIIa was mixed into whole blood prior to combining with chitosaneGP, (2) 3 mL of clotting factor (thrombin or rhVIIa þ TF) was ''painted'' on the drilled defect prior to loading a drop of liquid chitosaneGP/blood [ Fig. 4(B) and (C), Table I ]. Addition of rhFVIIa to chitosaneGP/blood mixtures prior to delivery slightly diminished in situ solidification time to 3.75 min, but the effect was not significant [Fig. 4(C), condition 2] . Painting of the defect surface with rhFVIIa þ TF w60 s prior to delivery of chitosaneGP/blood generated the most rapid in situ-solidifying implants, 1.5 min [P ¼ 0.013, Fig. 4(C), condition 3] . Painting of the defect surface with thrombin w60 s prior to delivering the implant slightly shortened the average in situ solidification time to 3.5 min, but this effect was not significant [ Fig. 4(C Our study has further elucidated the solidification mechanisms of a neutral chitosaneGP/blood mixture, which generates a cytocompatible implant used for cartilage repair 17e19 . ChitosaneGP/blood mixtures exhibited an increased initial viscosity by thrombin-independent mechanisms as no significant amount of TAT was detected until 15 min after increased viscosity was observed. Higher viscosity of bloodepolymer mixtures could be related to chitosan precipitation or gelation at blood pH which is above the chitosan pKa 35 , to early platelet activation, or to the agglutination of RBCs by chitosan, which has also been previously observed by ourselves and others 17,21e23 . ChitosaneGP solutions were therefore pro-coagulant in that they generated rapid and low-level platelet activation of the mixture. The latter observation is in agreement with previous reports showing that purified platelets can bind to chitin, to chitosan, and to fibrinogen adsorbed onto chitosan via GPIIb/IIIa integrin receptors 36, 37 . Since tPA only partly depressed chitosaneGP/blood clot tensile strength, this demonstrated that both fibrin and chitosan each contributed to the tensile mechanical properties of the hybrid clot. ChitosaneGP/blood clot resistance to tPA provides direct evidence that incorporation of chitosan into whole blood gives rise to a dual fibrinepolysaccharide clot scaffold that is physically more stable than whole blood clots. Therefore hybrid blood clot implants have the potential to sustain the ensuing wound repair response compared to normal whole blood clots.
Platelet activation is known to support the intrinsic clotting cascade 38, 39 , however early and minor platelet activation induced by chitosaneGP was insufficient to accelerate thrombin generation. The more gradual solidification of chitosaneGP/blood relative to whole blood could be related to the 25% dilution of whole blood components, which depresses fibrinogen concentration 40 , to binding of chitosan with fibrinogen 41 , to activation of platelets without aggregation in the chitosaneGP/blood mixture, or to slower diffusion Treatment Group Table I for number of defects per treatment group): (1) no clotting factor, (2) rhFVIIa pre-mixed with whole blood, (3) rhFVIIa þ TF deposited on defect surface w60 s prior to implant, (4) IIa deposited on defect surface w60 s prior to implant, (5) IIa deposited on defect surface 10 s prior to implant. *P < 0.05 with respect to implant with no clotting factor.
of clotting factors, to their substrate. However it should be noted that the TEG sample cup is made of a non-clotactivating plastic material that does not reflect in vivo conditions, where chitosaneGP/blood implant interacts with components present in the dé brided cartilage surface such as tissue factor, collagens and extravascular blood from the drilled subchondral bone.
CLOTTING FACTORS DECREASED CLOTTING TIME OF CHITOSANeGP/BLOOD IN VITRO AND IN VIVO
All of the clotting factors tested reduced the in vitro clotting time of chitosaneGP/blood, and of unmodified whole blood, similar to what is routinely observed using TF to induce in vitro coagulation of minimally modified blood and anti-coagulated whole blood 31, 42 . Since TF alone induced the most rapid solidification of chitosaneGP/blood, this suggests that plasma FVII/FVIIa present in the polymereblood mixtures was capable of rapidly complexing with TF. Rapid coagulation of chitosaneGP/blood in the presence of TF is therefore highly compatible with the natural mechanisms in place to ensure hemostasis of extravascular blood.
Pre-application of rhFVIIa þ TF and thrombin in vivo to the defect surface reduced the in situ solidification time to 1.5 and 2 min, respectively, which represents an important advance towards improving the clinical ease-of-use of chitosaneGP/blood implants. Our data suggest that pre-applied clotting factors induced a more rapid clot activation of the implant, and a more rapid hemostasis of the bleeding drill holes, thus contributing to a faster and more reproducible in situ implant solidification time. Even though instant solidification of the implant may be preferred, whole blood coagulation which drives implant solidification is known to require a lag phase during which cellular and enzymatic events need to take place before fibrin polymerization can begin 25, 32 . We are aware that our evaluation of in situ solidification time by the surgeon's observations is somewhat subjective. Even so, our methodology was sufficient to demonstrate that it is important to minimize the delay between delivery of thrombin and implant. Given the naturally high concentration of antithrombin in whole blood 39 , it is possible that applied thrombin can become gradually inactivated when coming into contact with subchondral blood. Therefore contact between thrombin and the polymereblood mixture should ideally occur within 10 s, which in the absence of a co-delivery device could be a limiting factor in clinical practice. By comparison, exposure of TF to whole blood is expected to further activate TF, which could explain why TF þ rhVIIa still accelerated implant solidification even after a w60 s delay in pre-loading. Another limitation of our in vivo study was the use of human clotting factors in a rabbit model, although pilot ex vivo tests showed that rabbit blood coagulated more rapidly when exposed to all of the human clot factors used (unpublished observations). For clinical applications, human thrombin is preferred over bovine thrombin, given that some patients can develop antithrombin antibodies after even a one-time exposure to bovine thrombin 43 . Our study was partly motivated by the knowledge that many clotting factors promote therapeutic effects in wound repair. Tissue factor was previously shown to stimulate angiogenesis 44 and bone repair in human patients receiving maxillary bone grafts 25 . Thrombin promotes cell migration and proliferation of many cell types implicated in wound healing of osteochondral defects 45e47 and stimulates angiogenesis 48 . ChitosaneGP/blood clots demonstrated a longer TAT generation, and sustained levels of PF4, which could be beneficial to acute repair processes. Platelet factors such as PF4 are known to elicit innate immune cells 49 and since innate immune activation, angiogenesis, and bone repair have all been identified in the mechanisms of repair by chitosan clot implants 15, 17, 19 addition of clotting factors such as purified thrombin, recombinant TF or rhFVIIa have the potential to contribute even further the quality of hyaline repair elicited by these hybrid implants.
Conclusions
ChitosaneGP/blood mixtures solidified through coagulation processes involving thrombin generation, fibrin polymerization and platelet activation and achieved a clot tensile strength similar to whole blood clots. Once solidified, hybrid clots maintained partial tensile strength in the presence of tPA. Hybrid clots demonstrate practical advantages over normal blood clots, as chitosan physically stabilized the clot from lysis and in addition stabilized platelet factor 4 and TAT against rapid degradation in serum after clotting. Clotting factors of the extrinsic clotting cascade and thrombin can be used to accelerate in situ solidification of injectable chitosaneGP/blood implants in drilled articular cartilage lesions in vivo. Clotting factors have the potential to enhance the practical use, the residency, and therapeutic activity of polymereblood implants.
